Brookstone Capital Management Catalyst Pharmaceuticals, Inc. Transaction History
Brookstone Capital Management
- $6.01 Billion
- Q3 2024
A detailed history of Brookstone Capital Management transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Brookstone Capital Management holds 33,506 shares of CPRX stock, worth $734,451. This represents 0.01% of its overall portfolio holdings.
Number of Shares
33,506
Previous 33,506
-0.0%
Holding current value
$734,451
Previous $519,000
28.32%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding CPRX
# of Institutions
325Shares Held
94.1MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$410 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$176 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$137 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$125 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$66.2 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.25B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...